Global Leading Market Research Publisher QYResearch announces the release of its latest report “Clazosentan Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This report provides a comprehensive analysis of the global clazosentan drug market, directly addressing the most urgent unmet medical need in neurocritical care: preventing cerebral vasospasm and delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH). For hospital pharmacy directors, neurointensivists, and pharmaceutical investors, the clinical and economic stakes are substantial—cerebral vasospasm affects up to 70% of aSAH patients and remains a leading cause of death and long-term disability despite existing therapies.
Clazosentan, a selective endothelin-A (ET-A) receptor antagonist, represents a mechanistically distinct approach to vasospasm prophylaxis. Unlike nimodipine (the only FDA-approved drug for DCI prevention, approved since 1988), clazosentan directly targets endothelin-1, the most potent endogenous vasoconstrictor identified to date. Elevated endothelin-1 levels in cerebrospinal fluid correlate strongly with vasospasm severity, providing a compelling biological rationale for ET-A receptor blockade.
According to QYResearch’s proprietary data, the global clazosentan drug market was valued at approximately US98millionin2025andisprojectedtoreachUS98millionin2025andisprojectedtoreachUS 178 million by 2032, growing at a CAGR of 8.9% during the forecast period 2026-2032. This growth trajectory reflects regulatory approvals in Japan and South Korea, ongoing clinical development, and expanding real-world evidence supporting selective use in high-risk patient populations.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983682/clazosentan-drug
1. Market Definition and Clinical Indication
Clazosentan is a small-molecule, selective endothelin-A receptor antagonist administered intravenously for the prevention of cerebral vasospasm, cerebral infarction, and delayed ischemic neurological deficits (DIND) following aneurysmal subarachnoid hemorrhage. The drug is currently approved in Japan and South Korea, with regulatory submissions pending in additional territories. Idorsia Pharmaceuticals is the sole manufacturer and global developer.
The market research landscape for clazosentan is defined by three key clinical endpoints:
- Angiographic Vasospasm: Radiographically confirmed vessel narrowing (primary efficacy endpoint in Phase II trials)
- Vasospasm-Related Cerebral Infarction: Permanent ischemic injury detected on follow-up imaging
- Delayed Ischemic Neurological Deficits (DIND): Clinically symptomatic deterioration attributable to vasospasm
Within product segmentation, the 150 mg vial dominates market share (approximately 85-90% of revenue), as this corresponds to the standard daily dosing regimen (10-15 mg/hour continuous IV infusion for up to 14 days). The “Other” segment includes research-grade formulations and smaller vial sizes for dose titration studies. Hospital inpatient settings account for over 95% of administration, with clazosentan utilization concentrated in neurocritical care units and stroke centers.
2. Clinical Efficacy: Meta-Analysis Evidence from 2025
Recent high-quality meta-analyses published in 2025 have substantially clarified clazosentan’s efficacy and safety profile. A systematic review and meta-analysis by Abunada et al. (BMC Neurology, October 2025), encompassing 13 reports with 5,728 patients, demonstrated statistically significant risk reductions across multiple endpoints:
| Clinical Endpoint | Risk Ratio (95% CI) | P-value |
|---|---|---|
| Vasospasm-related cerebral infarcts | RR = 0.56 (0.42-0.76) | p = 0.0002 |
| Delayed Ischemic Neurological Deficits (DIND) | RR = 0.67 (0.55-0.80) | p < 0.0001 |
| Incidence of vasospasm | RR = 0.54 (0.42-0.69) | p < 0.00001 |
When compared against fasudil (a Rho-kinase inhibitor commonly used in Asian markets), clazosentan demonstrated superior efficacy: lower incidence of vasospasm (RR = 0.44, p = 0.0004) and vasospasm-related cerebral infarcts (RR = 0.27, p = 0.002). Importantly, the analysis identified dose-dependent effects: higher doses (10-15 mg/h) showed particular benefit, especially in patients undergoing surgical clipping versus endovascular coiling.
A separate meta-analysis by Raja et al. (Neurosurgical Review, January 2025), focusing on eight RCTs with 3,186 participants, confirmed these findings with consistent effect sizes (vasospasm-related cerebral infarction RR = 0.56, DIND RR = 0.67). However, this analysis found no significant effect on overall mortality (p = 0.48), highlighting that reducing vasospasm does not automatically translate to survival benefit—a critical nuance for health technology assessment.
3. Safety Profile and Unmet Challenges
The adoption of clazosentan has been constrained by a well-documented safety profile requiring vigilant patient monitoring. Pooled analyses demonstrate significantly increased risks of:
- Hypotension: Requires dose adjustment or vasopressor support in 15-20% of patients
- Pulmonary complications: Including pulmonary edema and pleural effusion (approximately 2-3x placebo rates)
- Anemia and fluid retention: Particularly in elderly or hepatically impaired patients
The REACT trial (published in Journal of Neurosurgery, January 2025), a prospective Phase III study randomizing 409 patients across 74 international sites, failed to demonstrate a statistically significant reduction in clinical deterioration due to DCI (15.8% clazosentan vs. 17.2% placebo; RRR 7.2%, p = 0.734). While rescue therapy requirements were reduced (10.4% vs. 18.1%; RRR 42.6%), the trial’s neutral primary outcome underscores the complex relationship between angiographic vasospasm and clinical deterioration—a phenomenon sometimes termed “vasospasm dissociation.”
4. Competitive Landscape: Regional Market Share Dynamics
The clazosentan drug market is concentrated, with Idorsia Pharmaceuticals holding 100% market share as the sole manufacturer (exclusivity maintained through composition-of-matter patents expiring 2028-2030). However, market access is geographically segmented:
- Japan: Leading market size (approximately 55-60% of global revenue), following Ministry of Health, Labour and Welfare (MHLW) approval based on Phase III trials demonstrating efficacy in Japanese populations. The higher incidence of aSAH in Japan (2-3x global average) creates favorable market conditions.
- South Korea: Second-largest market (15-20% share), with approval granted and reimbursement negotiations ongoing.
- European Union & North America: Limited commercial availability (5-10% combined share), primarily through named patient programs and clinical trials. The REACT trial’s neutral outcome has delayed regulatory submissions, though subgroup analyses suggest potential benefit in surgically clipped patients with thick subarachnoid clots.
Idorsia Pharmaceuticals’ annual report (2024) indicated that clazosentan generated CHF 42 million (approximately US$ 48 million) in net sales, with Japanese operations contributing 78% of total revenue. The company’s pipeline includes an oral formulation (Phase I) and combination studies with nimodipine.
5. Unique Industry Observation: Discrete vs. Continuous Care Models
A distinctive industry dynamic rarely highlighted in standard market reports is the divergence between discrete and continuous care delivery models within the neurocritical care setting.
In discrete care models (typical of North American and European hospitals with protocol-driven, time-limited aSAH management), treatment decisions are made at admission and adjusted at predefined intervals (e.g., Days 3, 7, 14). This model favors medications with predictable kinetics and minimal monitoring requirements—explaining nimodipine’s continued dominance despite modest efficacy.
In continuous care models (predominant in Japan and South Korea, with higher nursing ratios and real-time hemodynamic monitoring), clazosentan’s requirement for intensive blood pressure management and fluid status assessment is operationally feasible. Japanese neurocritical care units routinely achieve nurse-to-patient ratios of 1:1 or 1:2, compared to 1:4 or higher in Western settings.
This operational distinction directly informs market forecasts: Clazosentan adoption will accelerate in markets willing to invest in continuous monitoring infrastructure. Tele-ICU platforms and automated vasopressor titration systems (adoption up 34% in US academic centers since 2024) may reduce the monitoring burden, potentially opening North American markets by 2028-2029.
6. Market Outlook and Strategic Recommendations for 2026-2032
By 2032, the global clazosentan drug market size is expected to reach US$ 178 million, growing at an 8.9% CAGR. Japanese market share will decline from 60% to 45-50% as South Korean and Chinese markets expand. However, three unresolved challenges persist:
- Functional outcome discordance: Despite reducing radiographic vasospasm and cerebral infarction, clazosentan has not consistently improved modified Rankin Scale (mRS) scores at 12 weeks—a requirement for regulatory approval in most Western jurisdictions.
- Optimal patient selection: Current evidence supports use in surgically clipped patients with thick, diffuse subarachnoid clots (modified Fisher Grade 3-4). Treating unselected aSAH patients dilutes efficacy signals and increases adverse events.
- Competition from next-generation ET-A antagonists: At least three compounds are in preclinical development with improved receptor selectivity and oral bioavailability, though none are expected to reach Phase III before 2029.
For hospital formulary committees and procurement managers, this market research suggests:
- For Japanese and South Korean hospitals: Clazosentan is appropriate for high-risk surgical clipping patients with thick SAH clots. Standardize administration protocols and implement hemodynamic monitoring checklists.
- For North American and European institutions: Consider clazosentan on a case-by-case basis through pharmacy-and-therapeutics review, pending local outcomes data.
- For investors: Monitor Idorsia’s partnering announcements (likely 2026-2027) for ex-Asia commercialization. The expiration of composition-of-matter patents (2028-2030) may open generic competition, though formulation and method-of-use patents provide extended protection.
The complete report, including Full TOC, 28 data tables, 22 figures, and detailed regulatory analysis across 8 countries, is available via the sample PDF link above.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
